---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036503"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:26:50.979540+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Trevi's Haduvio meets Phase 2a RIVER primary endpoint; 57% placebo-adjusted cough reduction

## Summary
- Primary endpoint: 67% reduction from baseline in 24-hour cough frequency; 57% placebo-adjusted (p<0.0001).
- 84% of Haduvio patients had ≥30% reduction vs 29% placebo; early response at Day 7 (27 mg BID).
- Severe cough subgroup (20+ coughs/hr): 66% reduction; moderate (10-19/hr): 68% reduction (p<0.0001).
- Safety profile consistent with prior Haduvio trials; no treatment-emergent serious adverse events.
- Trevi plans to discuss results with FDA and initiate next study after FDA input.

## SEC filing metadata
- accession: 0000950170-25-036503
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017025036503/0000950170-25-036503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017025036503/trvi-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036503
- JSON: https://secwatch.observer/filing/0000950170-25-036503.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.